Influence of antiviral therapy on survival of patients with hepatitis B-associated hepatocellular carcinoma undergoing transarterial chemoembolization by Li, Bing et al.
Li et al 
Trop J Pharm Res, August 2017; 16(8): 1997  
 
Tropical Journal of Pharmaceutical Research August 2017; 16 (8): 1997-2005 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v16i8.33 
Original Research Article 
 
 
Influence of antiviral therapy on survival of patients with 
hepatitis B-associated hepatocellular carcinoma 
undergoing transarterial chemoembolization 
 
Bing Li1, An Chen2, Xilin Du2 and Jianxing Zhan3* 
1Department of General Surgery, Xi’an Worker’s Hospital, Xi’an, Shanxi 710100, 2Department of General Surgery, Tangdu 
Hospital, Xi’an, Shanxi, 710006, 3Department of Hepatobiliary Surgery, Xi’an Aerospace General Hospital, Xi’an, Shanxi 
710100, China 
 
*For correspondence: Email: judny.mouttet9910@hotmail.com; Tel/Fax: 0086-029-85644119 
 
Sent for review: 6 March 2017        Revised accepted: 18 July 2017 
 
Abstract 
Purpose: To examine the prognostic value of antiviral therapy among hepatocellular carcinoma (HCC) 
patients undergoing transarterial chemoembolization (TACE). 
Method: A total of 356 patients with HCC undergoing TACE were recruited for the purpose of current 
study. All the patients were categorized into two groups; antiviral (n = 132) and non-antiviral group (n = 
224). All the clinical and laboratory parameters were noted at baseline. Patients were then followed up 
for five years. The mortality rates in two groups were evaluated with Kaplan-Meier estimate. 
Results: The average age of the participants was 51.2 ± 6.17 years. A majority (329; 92.4 %) of the 
patients were male while females constituted only 7.6 %. During five years follow-up period, a total of 
274 (76.9 %) died, with 89 patients belonging to the antiviral group while the remaining 185 patients 
were in the non-antiviral group. Mortality rate significantly differed between the antiviral and non-antiviral 
groups (67.4 % versus 82.5 %, p = 0.028). The results of Cox regression demonstrated that being a 
smoker, low serum albumin, local ablation and resection decreased overall survival while female 
gender, antiviral therapy, and early tumor site-node-metastatis (TNM) staging increased overall survival. 
Conclusion: Antiviral therapy for underlying hepatitis B in HCC patients undergoing TACE prolongs 
overall survival and prevents or delays reactivation of tumor. 
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Hepatocellular carcinoma (HCC) is a primary 
liver cancer and among one of the most fatal and 
prevalent tumors all over the world.  It is the fifth 
most prevalent type of cancer among human 
beings globally and the seriousness of disease 
can be attributed to the fact that it is ranked third 
for cancer associated fatalities [1] According to 
global cancer statistics, HCC is the most 
prevalent histological subtype that causes 70 - 
80 % of total liver cancer burden [2]. In 2012, the 
incidence of liver cancer cases was estimated to 
be 782, 500 cases while the number of mortality 
cases was estimated to be around 745, 500 
cases. Surprisingly, 50 % of both incident cases 
and mortal cases belonged solely to China [3]. 
China, one of the largest countries in Asia, 
accounts for the maximum prevalence of HCC 
with highest fatality rate associated with the 
disease. Cirrhosis related to hepatitis B and C 
virus is considered major cause of HCC. In the 
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developed countries such as United States (US), 
United Kingdom (UK), Australia, Northern 
America and Japan, HCV is the prevalent cause 
of HCC while in Asian countries, especially 
China; HBV is the most prevalent reason of HCC 
[4]. Apart from viral factors, there are various 
environmental, host genetics and demographic 
factors that primarily contribute to the increasing 
risk of HCC [5]. Since hepatitis B virus (HBV) is a 
well-established viral factor of increased risk of 
HCC and poor prognosis of disease, it is 
therefore extremely crucial to manage the 
underlying HBV along with the prime liver 
disease. 
 
Two decades ago, HCC was considered a rare 
disease that was diagnosed in advanced stages 
only and there were very limited palliative and 
therapeutic options [6]. However, with increased 
incidence and prevalence of the disease, various 
new treatments have been used for early 
screening as well as treatment of the disease. 
Among such advances, liver transplantation is 
considered as curative for selected patients while 
transarterial chemoembolization (TACE) as 
palliative treatment is extensively used for HCC 
[7]. TACE is a minor invasive procedure that is 
used to block hepatic artery and administer 
chemotherapy directly to the tumor site through a 
catheter. TACE is different from systemic 
chemotherapy since it involves direct delivery of 
chemotherapeutic agents to the liver tumor site 
only [8]. Since TACE is a locoregional therapy, 
the chances of HBV reactivation gets potentially 
higher with this therapy [9]. Recently few short 
term studies have shown that concomitant use of 
antiviral therapy with TACE could ultimately 
decrease the risk of HBV reactivation. 
 
Despite various therapeutic treatments, there is 
no significant improvement observed in survival 
trends of HCC patients. [6] The possible reasons 
might involve reactivation of HBV after TACE in 
the long run. In the current study, the overall 
survival was estimated and compared between 







The ethical approval for the study was obtained 
from the Research Ethical Review Board (RERB) 
of the Xi`an Worker`s Hospital (ref no. 
XWR/RERB/2015/HR-053). Thet study was 
carried out in accordance with international 
ethics on human research [10]. A written 
permission was secured to obtain and describe 
the data. All patient information was anonymized 
and identification of study participants was not 




From January 2009 to December 2011, hospital 
database was retrospectively retrieved to identify 
participants diagnosed with Hepatitis B surface 
antigen (HBsAg) HCC followed by TACE. 
Diagnosis of HCC was based on histological 
findings or the European Association for the 
Study of Liver (EASL) guidelines. Patients were 
followed up for the period of five years until 




Apart from demographic data, baseline 
examinations before TACE included complete 
blood count, serum liver tests, chest radiography 
and DNA quantification of serum hepatitis B 
virus. The quantification of HBV DNA was 
performed via detection of HB surface antigen 
(HBsAg), HB surface antibody (HBsAb), HB e 
antigen (HBeAg), HB e antibody (HBeAb), anti-
hepatitis C antibody (HCV Ab), HB core antigen 
(HBcAg). Polymerase chain reaction (PCR) was 
used to detect HBV DNA viral load. The 
quantitative fluorescence PCR kit used had a 
lower detection limit of 100 IU/ml. Both intra-
operative interpretations and imaging were used 
to evaluate the characteristics of tumor, and 
tumor site-node-metastatis (TNM) staging 
according to the Union of international cancer 
control. Within 7 days of all initial examinations, 
all patients received TACE with the following 
chemotherapeutic agents (doses mentioned as 
per session dose; epirubicin (60 mg) with or 
without mitomycin (6 mg), lobaplatin (50 mg), 
carboplatin (300 mg) and floxuridine (500 mg). 
No particular combination of chemotherapeutic 
agents was used. The choice of 
chemotherapeutic agent with dose of lipiodol 
emulsion and/or gelform was done on case to 




The inclusion criteria for the current study were 
as follow: a positive HB surface antigen (HbsAg), 
adequate baseline liver and renal function that 
was assessed via Child-Pugh grade A and serum 
creatinine level < 124 micro mol/L, respectively 
and lastly good tolerance for TACE. All the 
patients selected for the current study had 
minimum follow-up of six months. The same 
clinical and laboratory data that was recorded at 
baseline before TACE were recorded during 
follow-up.  
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Patients with negative HBsAg, co-infection with 
other hepatic virus, human immunodeficiency 
(HIV) infection, inadequate functioning liver 
(Child-Pugh grade B/C), administration of 
hepatotoxic medications, interferon and/or 
corticosteroid (3 months prior to TACE), any 
other malignant disease other than HCC or 
severe no-malignant chronic illness, obstructive 
jaundice, hepatic encephalopathy were excluded. 
In order to rule out possible adverse outcomes of 
TACE, all patients who experienced severe 
complications after TACE or adverse effects 
immediately after TACE or at least within one 
month were excluded. Patients having follow-up 







Transcatheter arterial chemoembolization was 
performed as follows: A catheter was inserted 
into the hepatic artery directly supplying blood to 
the tumor site. As catheter tip approached the 
tumor site, one or a combination of anti-cancer 
drugs mixed with lipiodol was injected slowly. 
Gelation sponge particles were injected in cases 
when chemoembolized artery did not show 
stagnant blood flow [11,12].  
 
The changes in load of HBV DNA after TACE 
were categorized into three groups [13]; 
 
1. HBV reactivation was defined as ≥ ten-fold 
increment in the load of HBV DNA as 
compared to the values at baseline or 
undetectable HBV DNA from baseline. 
Moreover, it might also be considered viral 
reactivation if there is more than 200 IU/mL 
after TACE. 
 
2. HBV downregulation was referred to ≤ ten-
fold decline in HBV DNA when compared with 
baseline or absence of detectable level DNA 
from baseline and HBV DNA > 200 IU/mL at 
baseline before TACE. 
 
3. Stability: Patients were categorized as stable 
if they don’t fall in categories of HBV 




All the recruited patients were followed up and 
subsequent treatments such as hepatectomy, 
local ablation, liver transplantation or sorafenib 
were recommended after initial TACE. None of 
the patient in the current cohort received liver 
transplantation. The selection of subsequent 
therapy was done on the basis of patient 
characteristics and response to treatment. 
 
Oral antiviral therapy 
 
The choice of antiviral therapy was solely based 
on availability of drug. In the current study, 





The normality of quantitative data was examined 
by Kolmogorov-Smirnov test. Measures of 
central tendency and dispersion were calculated 
for continuous data. Frequencies along with 
proportions (%) were used for categorical 
variables. Group comparison was performed by 
Chi-Square test, Student’s t-test or one-way 
ANOVA, where appropriate [14].  
 
Cox proportional hazard models were estimated 
to determine the association of variables with 
overall survival, were used. The variables with 
significant univariate p-values were subjected to 
multivariate regression analysis (backward 
elimination logistic regression analysis). Kaplan-
Meier estimates with log rank tests were carried 
out for survival analysis. Overall survival (OS) 
was estimated from the date of TACE initiation to 
the completion of follow-up or death, whichever 
occurred first. 
 
All the analyses were carried out using SPSS 
version 20. A codebook for categorical variables 
was maintained where presence of an outcome 
was denoted as “one (1)” while absence was 
coded as “zero (0)”. All statistical inferences were 




Baseline data of participants 
 
The baseline clinico-laboratory characteristics of 
study participants are demonstrated in Table 1. A 
total of 356 patients (mean age: 51.2 ± 6.17 yr) 
were recruited to participate in the current study. 
Majority 329 (92.4 %) of the patients were male 
while females constituted only 7.5 % of study 
population. Out of 356 patients involved, 132 (37 
%) patients had antiviral therapy in the form of 
nucleotide or nucleoside analogs; 73 (55.3 %) 
received Entecavir while remaining 59 (44.6 %) 
received Lamivudine only. Antiviral drugs were 
used for a median period of 23.5 months. 
Antiviral therapy related serious adverse effects 
were not observed and hence not mentioned 
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here. With respect to laboratory parameters, 
bilirubin levels and prothrombin time were 
significantly higher in antiviral group while 
albumin was higher in the non-antiviral group. 
With respect to UICC staging system, maximum 
number of patients were in stage IIIa (31.4 %) 
and IIIb (27.8 %) while only 11 (3 %) of patients 
belonged to stage IV.  
 
A total of 101 (28.3 %) patients were HbeAg 
positive with majority 47 (35.6 %) patients 
belonged to the antiviral group. The mean 
baseline HBV DNA was significantly higher in 
antiviral group as compared to non-antiviral 
group (p = 0.00). This explains the use of 
antiviral therapy in high viral load patients. The 
higher viral load can also be observed with 
majority (54.5 %) of patients in the antiviral group 
undergoing > 1 cycle of TACE while only 34.3 % 
patients had > 1 TACE cycle in the non- antiviral 
group (p = 0.00). The proportion of local ablation 
was also more profound in the antiviral group 
than non-antiviral group (29.5 % versus 17.8 %, 
p = 0.04). With respect to chemotherapeutic 
agents, there was equal distribution between two 
groups. 
 
Changes in viral DNA load after TACE 
 
After the initial TACE, majority 252 (70.7 %) had 
stable HBV DNA while downregulation was 
observed in 62 (17.4 %) patients. Reactivation of 
HBV DNA after initial TACE was observed in 
total 42 patients. Out of these 42 patients, only 6 
(4 %) HBV reactivation cases were observed in 
the antiviral group while the remaining 36 (16 %) 
cases of HBV reactivation were noted in the non-
antiviral group (p = 0.00). 
 
Table 1: Baseline characteristics of the entire study cohort 
 







Age 51.2 ± 6.17 49.8 ± 5.83 52.6 ± 6.52 0.49 
Male gender 329 (92.4%) 123 (93.1%) 206 (91.0%) 0.08 
Current smoking 102 (28.6%) 36 (27.2%) 66 (29.4%) 0.07 
Serum     
Hemoglobin (g/L) 135.9 ± 9.85 135.7 ± 8.5 136.1 ± 11.2 0.64 
White blood cells  6.36 ± 1.74 6.15 ± 1.35 6.57 ± 2.13 0.41 
Platelets 167.2 ± 14.59 163.4 ± 10.5 171.0 ± 18.69 0.06 
Hepatic function      
Serum albumin (g/L) 38.9 ± 2.35 38.8 ± 2.5 39.1 ± 2.2 0.04 
Total bilirubin (g/L) 17.6 ± 4.9 18.5 ± 5.3 16.7 ± 4.5 0.03 
Prothrombin time (sec) 12.3 ± 3.9 12.5 ± 3.6 12.1 ± 4.2 0.04 
APTT (sec) 27.5 ± 3.6 27.9 ± 3.9 27.1 ± 3.3 0.12 
ALT (U/L) 56.9 ± 16.4 61.5 ± 14.3 52.3 ± 18.5 0.06 
AST (U/L) 85.35 ± 29.5 89.5 ± 22.5 81.2 ± 36.5 0.06 
Hepatitis B      
HbeAg positive 101 (28.3%) 47 (35.6%) 54 (24.1%) 0.04 
HBV DNA(log10IU/ml) 5.01 ± 1.61 5.61 ± 1.82 4.42 ± 1.41 0.00 
TNM staging     
I 67 (18.8%) 22 (16.7%) 45 (20.1%) 0.02 
II 41 (11.5%) 23 (17.4%) 18 (8.04%) 0.00 
IIIa 112 (31.4%) 45 (34.1%) 67 (29.9%) 0.04 
IIIb 99 (27.8%) 28 (21.2%) 71 (31.7%) 0.03 
IIIc 26 (7.3%) 8 (6.0%) 18 (8.0%) 0.73 
IV 11 (3.0%) 6 (4.5%) 5 (2.2%) 0.27 
TACE cycles(>1) 149 (41.8%) 72 (54.5%) 77 (34.3%) 0.00 
Subsequent therapy     
Local ablation 79 (22.1%) 39 (29.5%) 40 (17.8%) 0.042 
Resection 37 (10.3%) 13 (9.8%) 24 (10.7%) 0.58 
Sorafenib therapy 21 (5.8%) 8 (6.0%) 13 (5.8%) 0.95 
Chemotherapeutic agent     
1 93 (36.3%) 31 (23.4%) 62 (27.6%) 0.82 
>2 263 (73.8%) 101 (76.5%) 162 (72.3%) 0.73 
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Overall survival in the entire cohort 
 
A total of 274 (76.9 %) died during follow-up 
period. Out of the 274 mortal cases, 89 cases 
belonged to the antiviral group while 185 patients 
died from the non-antiviral group. The mortality 
rate was significantly different between antiviral 
and non-antiviral group (67.4 % versus 82.5 %, 
p-value = 0.028). The overall survival rates for 
the entire cohort at 1, 2, 3, 4, 5 years were 50, 
33.1, 23.5, 19.6 and 13.4 %, respectively (Figure 
1). In each year of follow-up, the survival rates 
for the antiviral group were higher than the non- 
antiviral group i.e. 1st year (56.8 % versus 45.9 
%), 2nd year (40.1 % versus 29 %), 3rd year (31.8 
% versus 18.7 %), 4th year (27.2 % versus 15.1 
%), 5th year (19 % versus 10.2 %). The median 
survival time was significantly higher for patients 
in antiviral group when compared to those in 
non-antiviral group (log rank p-value = 0.032). 
 
Factors associated with overall survival in the 
entire cohort 
 
All the clinical and demographic variables in 
Table 1 were subjected to univariate analysis. 
The significant univariate factors (p < 0.05) were 
tested by multivariate regression using backward 
elimination approach (age, male gender, 
smoking status, TNM staging, albumin, bilirubin, 
ALT, AST, antiviral treatment, local ablation, 
resection and prothrombin time). Multivariate 
analysis demonstrated male gender, smoking 
status and higher albumin level were risk factors 
of low overall survival rates while TNM staging 
and antiviral treatment were associated with 
increased overall survival rates (Table 3). For the 
purpose of regression analysis, TNM staging was 
divided into early and late staging with stage 1 
and stage II classified as early TNM staging 
while stage III and IV were classified as late TNM 
staging. Table 3 shows that being smoker, low 
serum albumin, local ablation and resection 
decreases overall survival while female gender, 
antiviral therapy, early TNM staging increases 
overall survival. 
 
Figure 1: Kaplan-Meier curve comparing survival in HCC patients with antiviral treatment versus HCC 
patients without antiviral treatment (log rank = 0.03) 
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Table 3: Cox regression analysis to deteermine variables associated with overall survival (n = 356) 
 
Variable Univariate analysis Multivariate analysis 
HR 95%CI P-value HR 95%CI P-value 
Old age 0.75 0.63-0.97 0.015 0.69 0.73-1.08 0.724 
Female gender 2.74 1.24-5.79 0.027 2.44 1.15-6.73 0.013 
Smokers 0.65 0.28-0.51 0.024 0.39 0.21-0.69 0.048 
Serum albumin 0.86 0.72-0.89 0.038 0.61 0.57-0.92 0.015 
Total bilirubin 0.35 0.16-0.72 0.042 0.42 0.43-1.08 0.083 
PT 0.62 0.46-1.02 0.892    
APTT 0.29 0.91-1.32 0.381    
ALT 0.68 0.48-1.09 0.085    
AST 0.46 0.28-0.64 0.041 1.08 0.96-1.04 0.641 
HbeAg + 0.26 0.97-1.42 0.839    
HBV DNA 0.32 0.45-0.81 0.046 0.49 0.84-1.91 0.573 
TNM staging 
(early) 
2.83 1.25-2.83 0.002 2.62 1.12-3.79 0.012 
TACE cycle <1 1.27 0.10-1.79 0.273    
Local ablation 0.38 0.15-0.68 0.003 0.31 0.09-0.59 0.001 
Resection 0.31 0.37-0.87 0.001 0.25 0.24-0.73 0.001 
Sorafenib therapy 0.12 0.27-1.68 0.438    
Antiviral therapy 3.24 1.57-4.28 0.001 2.98 1.68-3.53 0.002 
Chemotherapeutic 
agent> 2 




A preliminary literature search showed paucity of 
data on prognostic significance of antiviral 
therapy among patients with HBV associated 
HCC scheduled to undergo TACE. However, few 
studies have addressed the impact of antiviral 
drugs on the survival among post-resection HBV 
associated HCC patients [15-18] Most of these 
studies have shown that antiviral therapy 
improves prognosis of HCC patients after 
resection and increases overall survival. In a 
longitudinal cohort study, data of 4569 HBV 
related HCC patients was recorded and were 
subsequently categorized into two groups in 
order to investigate  the risk of tumor recurrence 
between patients taking antiviral therapy and 
patients without antiviral therapy (518 versus 
4051). The authors found that the antiviral 
treated cohort had a lower risk of HCC 
recurrence (20.5 % versus 43.6 %) and improved 
overall survival (10.6 % versus 28.3 %) as 
compared to the non-treatment group [15].  
 
In a meta-analysis of nine cohort studies 
including a total of 551 patients (204 with antiviral 
treatment, 347 without antiviral treatment), the 
authors concluded that antiviral therapy 
decreases tumor recurrence and improves 
overall survival in HCC patients undergoing 
curative treatments [16]. Despite abundant data 
on promising benefits of antiviral treatments in 
patients undergoing curative treatment for HCC 
induced by HBV, there is still paucity of data on 
impact of antiviral treatment on the long-term 
outcomes of patients with HCC having TACE. 
 
On the basis of above mentioned gaps in the 
literature, the current study was designed to 
evaluate the effect of antiviral therapy in a cohort 
of hepatocellular carcinoma patients undergoing 
TACE. On the basis of antiviral therapy, patients 
were categorized into two groups i.e. HCC 
patients with and without antiviral therapy after 
TACE. The differences in clinical and 
demographic parameters were noted at baseline 
and factors contributing to overall survival were 
noted. Finally both patient groups were 
compared for overall upon completion of study.  
 
In the current study, patients on antiviral therapy 
showed improved overall survival compared to 
the non-treatment group. Of the total 274 mortal 
cases, 32.4 % cases belonged to the antiviral 
group while almost doubled cases (67.5 %) 
belonged to the non-antiviral group. The results 
of multivariate regression analysis showed 
antiviral therapy as the strongest independent 
predictor of overall survival with a HR of 2.98. 
This clearly shows that antiviral therapy offers 
survival advantage in HCC patients undergoing 
TACE. The exact mechanism by which antiviral 
therapy improves survival is unclear and several 
mechanisms have been proposed. One such 
proposed mechanism states that antiviral therapy 
improves survival mainly by reducing in HBV 
load i.e. decreased HBV DNA results in decrease 
viral replication [19]. As the viral load decreases, 
the genetic stability in hepatocytes is improved 
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that helps further regeneration. In a meta-
analysis, the authors reported the decrease in 
HCC recurrence with decreasing viral load [20]. 
In the current study, HBV reactivation was seen 
in 42 (11.7 %) patients after 6 months of initial 
TACE. Out of these 42 patients, 6 (14.2 %) 
patients were from the antiviral group while 
remaining 36 (85.7 %) patients were from the 
non-antiviral group. The exceptionally higher 
number of the non- antiviral patients with HBV 
reactivation confirms this mechanism. 
 
Other proposed mechanism states that reduction 
of hepatitis activity and chronic inflammation in 
remnant liver by the antiviral therapy improves 
hepatic functional reserve and helps patients to 
tolerate subsequent HCC treatment [21]. In 
present study, 54.5 % of patients with antiviral 
therapy received more than one TACE cycle 
compared to 34.3 % patients with non-antiviral 
therapy who received more than one TACE 
cycle. At baseline, tumor stages and hepatic 
function were comparable in two groups, it is 
postulated that preservation of liver function by 
the antiviral treatment resulted in multiple cycles 
of TACE. Similar results have been shown by 
other recently conducted studies in HCC patients 
[22,23].  
 
Aside from antiviral therapy, other prognostic 
factors that improved overall survival included 
female gender and early TNM staging. It is a 
well-documented fact that HCC is more prevalent 
among male gender. Various studies have 
shown improved survival in female patients with 
reasons attributing to genetic differences 
between males and females [24,25]. In the 
current study, a total of 108 patients had early 
tumor staging. According to guidelines, TACE is 
recommended for patients with intermediate to 
advance TNM staging while surgical resection, 
ablation are recommended first line treatments 
for early stage tumor.  
 
In present study these 108 patients underwent 
TACE as they had contraindications for surgery 
with major contraindication being tumor location. 
The results of multivariate analysis showed early 
stage TNM as significant prognostic factor of 
overall survival (2.6 HR). Similar findings were 
reported by Chan et al. who studied the impact of 
antiviral therapy on survival of HBV related HCC 
patients after hepatectomy [26]. Authors found 
that patients with early stage tumor had 
increased overall survival as well as increased 
disease free survival rates. These findings 
suggest the initiation of antiviral therapy in 
patients with HCC at an early tumor rather than 
late tumor stage.  
 
Limitations of the study 
 
The main limitation associated with the current 
study is its retrospective nature. As the data was 
not collected prospectively, there were many 
missing variables. Moreover, patients with 
complications after TACE were not selected for 
the current study, therefore the results of the 
current study cannot be generalized for all HCC 
patients undergoing TACE. Lastly, patients with 
hepatic complications were also excluded. As 
most of HCC patients had several hepatic and 
other complications, more studies are required to 
explore the role of antiviral therapy in such 
cases. A prospective randomized controlled trial 
is needed to validate the findings of this study 
and to address the gaps presented in present 
study. 
     .   
CONCLUSION 
 
The findings of the study suggest improvement in 
overall survival with antiviral therapy following 
TACE among patients with HBV-related HCC. 
Therefore, it seems that HCC patients would 
benefit more from anti-viral therapy after after 
TACE in terms of enhanced patients’ well-being 
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